Publication Name	World Journal of Clinical Oncology
Manuscript ID	17099
Country	Italy

Received	2015-02-12 14:56
Peer-Review Started	2015-02-14 08:39
To Make the First Decision	2015-03-06 10:09
Return for Revision	2015-03-15 19:16
Revised	2015-03-19 06:48
Second Decision	2015-05-08 17:40
Accepted by Journal Editor-in-Chief	2015-05-10 20:32
Accepted by Executive Editor-in-Chief	2015-05-18 17:27
Articles in Press	2015-05-18 17:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-07-23 15:10
Publish the Manuscript Online	2015-08-17 16:41

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Meta-Analysis
Article Title	Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Brigitta Badiani, Dario Maratea and Andrea Messori
Funding Agency and Grant Number
Corresponding Author	Dr. Andrea Messori, PhD, HTA Unit, ESTAV Toscana Centro, Regional Health Service, Via San Salvi 12, 50100 Firenze, Italy. andrea.messori.it@gmail.com
Key Words	Meta-analysis; Bayesian methods; Advancer gastric cancer; Second line therapy; Paclitaxel; Irino­tecan; Docetaxel; Ramucirumab
Core Tip	We carried out a Bayesian network meta-analysis to evaluate second-line treatments for advancer gastric cancer. After scanning the literature up to February 2015, 7 randomized controlled trials were inclu-ded in our meta-analysis in which the treatments for this disease condition and best supportive care (BSC) were evaluated according to overall survival (OS). Our meta-analysis investigated 21 direct or indirect comparisons. The difference in OS between paclitaxel vs BSC and ramucirumab + paclitaxel vs BSC was statistically significant, while the other comparisons showed no statistical difference. In conclusion, our results indicate that both paclitaxel and ramucirumab + paclitaxel determine a significant prolongation in survival in comparison with BSC.
Publish Date	2015-08-17 16:41
Citation	Badiani B, Maratea D, Messori A. Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis. World J Clin Oncol 2015; 6(4): 73-79
URL	http://www.wjgnet.com/2218-4333/full/v6/i4/73.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i4.73

Full Article (PDF)	WJCO-6-73.pdf
Full Article (Word)	WJCO-6-73.doc
Manuscript File	17099-Review.doc
Answering Reviewers	17099-Answering reviewers.pdf
Audio Core Tip	17099-Audio core tip.mp3
Biostatistics Review Certificate	17099-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	17099-Conflict-of-interest statement.pdf
Copyright License Agreement	17099-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	17099-Language certificate.pdf
Peer-review Report	17099-Peer review(s).pdf
Journal Editor-in-Chief Review Report	17099-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	17099-Scientific misconduct check.pdf
Scientific Editor Work List	17099-Scientific editor work list.pdf